We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DexCom (DXCM) Outpaces Stock Market Gains: What You Should Know
Read MoreHide Full Article
DexCom (DXCM - Free Report) closed the most recent trading day at $435.04, moving +1.06% from the previous trading session. The stock outpaced the S&P 500's daily gain of 0.69%. Elsewhere, the Dow gained 0.78%, while the tech-heavy Nasdaq added 0.28%.
Coming into today, shares of the medical device company had lost 17.34% in the past month. In that same time, the Medical sector lost 8.58%, while the S&P 500 lost 5.29%.
Wall Street will be looking for positivity from DexCom as it approaches its next earnings report date. This is expected to be February 10, 2022. In that report, analysts expect DexCom to post earnings of $0.86 per share. This would mark a year-over-year decline of 5.49%. Our most recent consensus estimate is calling for quarterly revenue of $696.68 million, up 22.46% from the year-ago period.
It is also important to note the recent changes to analyst estimates for DexCom. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 2.03% lower. DexCom is holding a Zacks Rank of #4 (Sell) right now.
Digging into valuation, DexCom currently has a Forward P/E ratio of 127.33. This represents a premium compared to its industry's average Forward P/E of 38.44.
The Medical - Instruments industry is part of the Medical sector. This group has a Zacks Industry Rank of 178, putting it in the bottom 31% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow DXCM in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
DexCom (DXCM) Outpaces Stock Market Gains: What You Should Know
DexCom (DXCM - Free Report) closed the most recent trading day at $435.04, moving +1.06% from the previous trading session. The stock outpaced the S&P 500's daily gain of 0.69%. Elsewhere, the Dow gained 0.78%, while the tech-heavy Nasdaq added 0.28%.
Coming into today, shares of the medical device company had lost 17.34% in the past month. In that same time, the Medical sector lost 8.58%, while the S&P 500 lost 5.29%.
Wall Street will be looking for positivity from DexCom as it approaches its next earnings report date. This is expected to be February 10, 2022. In that report, analysts expect DexCom to post earnings of $0.86 per share. This would mark a year-over-year decline of 5.49%. Our most recent consensus estimate is calling for quarterly revenue of $696.68 million, up 22.46% from the year-ago period.
It is also important to note the recent changes to analyst estimates for DexCom. These recent revisions tend to reflect the evolving nature of short-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 2.03% lower. DexCom is holding a Zacks Rank of #4 (Sell) right now.
Digging into valuation, DexCom currently has a Forward P/E ratio of 127.33. This represents a premium compared to its industry's average Forward P/E of 38.44.
The Medical - Instruments industry is part of the Medical sector. This group has a Zacks Industry Rank of 178, putting it in the bottom 31% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow DXCM in the coming trading sessions, be sure to utilize Zacks.com.